Colitis is not one disease. It is inflammation of the colon, and the right treatment depends entirely on what is causing that inflammation. Ulcerative colitis, microscopic colitis, infectious colitis, ischemic colitis, radiation colitis, and drug-induced colitis all look different under a microscope and respond to very different therapies. A steroid that rescues one type can be useless or even harmful in another. This makes getting the correct diagnosis the single most consequential step toward effective treatment.
Why the Type of Colitis Matters So Much
The colon has a surprisingly limited set of responses to injury. Whether the cause is an autoimmune attack, a disrupted blood supply, an infection, or radiation damage, the colon tends to respond with some combination of swelling, ulceration, and bleeding. That overlap is exactly why sorting out the cause requires endoscopy, tissue biopsies, lab work, and imaging rather than symptoms alone.1Diagnostic Histopathology. Colitides: diagnostic challenges and a pattern based approach to differential diagnosis Treating colitis “generically” with, say, a broad immunosuppressant risks missing an infection that needs antibiotics, or medicating away pain from ischemia that actually requires surgery. The sections below walk through the major types and the treatments that have the best evidence behind them.
Ulcerative Colitis, Mild to Moderate
Ulcerative colitis (UC) is an autoimmune condition limited to the colon, where inflammation starts at the rectum and spreads upward in a continuous pattern. Depending on how far up it extends, it may be classified as proctitis (rectum only), left-sided colitis, or pancolitis (the whole colon).2PubMed. Diagnosis and classification of ulcerative colitis This classification matters for treatment because someone with inflammation confined to the rectum may respond well to a rectal suppository or enema, while someone with pancolitis needs systemic oral medication.
The first-line drug for mild-to-moderate UC is mesalamine, a 5-ASA compound that works directly on the inflamed lining of the colon. In active disease, mesalamine produces response rates between roughly 40% and 70%, with remission rates of about 15% to 20%.3PubMed Central. The role of mesalamine in the treatment of ulcerative colitis Those remission numbers sound modest, but mesalamine’s safety profile is excellent compared with steroids or immune-suppressing drugs, which is why guidelines recommend trying it first at an optimized dose of at least 4 grams per day, sometimes combined with a 1-gram rectal dose.4Frontiers in Gastroenterology. The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis If mesalamine alone is not enough, a short course of oral corticosteroids (typically prednisone or budesonide) can help push a flare into remission, but steroids are bridge therapy, not a long-term plan.
Ulcerative Colitis, Moderate to Severe
When mesalamine and short steroid courses fail, or when the disease is severe from the start, doctors turn to biologics and newer small-molecule drugs. Five biologics have been approved for UC: infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab. These target specific parts of the immune system rather than suppressing it broadly.5PubMed. Biologic Therapy for Ulcerative Colitis Infliximab, given by infusion, was the first biologic used widely in UC and remains one of the most effective, particularly for inducing remission quickly.
A large network meta-analysis comparing biologics and small-molecule drugs head to head (indirectly, since trials are usually placebo-controlled) found that the oral JAK inhibitor upadacitinib ranked first for achieving clinical remission across all patient groups, including those who had already tried and failed an anti-TNF biologic. Infliximab ranked first for endoscopic healing.6PubMed. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis Real-world data support those findings: in one prospective study, over 80% of UC patients treated with upadacitinib achieved clinical remission by eight weeks.7PubMed Central. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience
Another newer option is etrasimod, an oral drug that modulates sphingosine-1-phosphate receptors. It has been approved for moderately to severely active UC after clinical trials showed it could both induce and maintain remission.8PubMed Central. Etrasimod for moderate to severe ulcerative colitis Having multiple oral options matters because many patients understandably prefer a pill over regular infusions, and having several classes of drug means there is usually something left to try when one approach stops working.
Crohn’s Disease Affecting the Colon
Crohn’s disease can involve any part of the digestive tract, but when it targets the colon it is sometimes called Crohn’s colitis. Unlike UC, Crohn’s inflammation can be patchy rather than continuous, and it can extend through the full thickness of the bowel wall. Many of the same biologics used for UC also work in Crohn’s colitis. The same real-world study mentioned above found that upadacitinib produced clinical remission in about 70% of Crohn’s patients by eight weeks.7PubMed Central. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience One key difference in management is that mesalamine, the workhorse for mild UC, has limited proven benefit in Crohn’s disease. Crohn’s patients who need ongoing therapy are typically escalated to immunomodulators or biologics earlier.
Dietary support also plays a more defined role in Crohn’s disease than in UC. The American Gastroenterological Association recommends the Mediterranean diet for Crohn’s patients, and several studies have shown that following it correlates with lower inflammatory markers and better quality of life.9PubMed Central. The Role of Diet in Crohn’s Disease: From Etiology to Evidence-Based Management The emphasis is on vegetables, fruits, legumes, whole grains, and olive oil while limiting ultra-processed foods and red meat. Diet alone does not replace medication for active disease, but it can help keep inflammation in check between flares.
Microscopic Colitis
Microscopic colitis is a sneaky diagnosis. The colon looks completely normal during a colonoscopy, and the inflammation only shows up under a microscope in biopsied tissue. It comes in two subtypes, collagenous colitis and lymphocytic colitis, and its hallmark symptom is chronic, watery, non-bloody diarrhea. It most often affects older adults and is sometimes triggered by medications like proton-pump inhibitors, NSAIDs, and certain antidepressants.
The first step in treatment is reviewing your medication list with your doctor and stopping anything that might be a trigger. Beyond that, oral budesonide is the clear frontrunner. It is effective at inducing remission in both collagenous and lymphocytic subtypes.10PubMed Central. Use of budesonide in the treatment of microscopic colitis The catch with budesonide is relapse: a systematic review and meta-analysis found that more than half of patients relapse after stopping the drug, with rates similar whether they had been on budesonide or placebo during the maintenance phase.11European Journal of Gastroenterology & Hepatology. Budesonide treatment for microscopic colitis: systematic review and meta-analysis That means many people end up on low-dose budesonide for the long haul, trying periodic tapers to see if they can get off it.12Nature Reviews Disease Primers. Microscopic colitis For those who cannot tolerate budesonide or keep relapsing, options are thinner: cholestyramine, bismuth subsalicylate, or in refractory cases, the same biologics used in IBD.
Infectious Colitis
The most consequential infectious cause of colitis is Clostridioides difficile (C. diff), a bacterium that thrives when antibiotics wipe out the normal gut flora. C. diff colitis ranges from mild diarrhea to life-threatening toxic megacolon. Treatment guidelines have shifted in recent years. Older protocols used metronidazole as the go-to for mild cases, but current first-line treatment favors vancomycin or fidaxomicin, both given by mouth.13PubMed. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives Fidaxomicin is generally preferred for a first recurrence because it causes less disruption to the rest of the gut microbiome.
Recurrence is a major problem with C. diff. Roughly one in five patients will have the infection return, and after two recurrences the risk of further episodes climbs steeply. For recurrent cases, fecal microbiota transplantation (FMT) has emerged as a highly effective therapy. In patients who also had underlying UC, FMT cured recurrent C. diff in about 91%, and most of those patients also saw improvement in their UC symptoms.14PubMed. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis Newer FDA-approved live biotherapeutic products, which are essentially standardized versions of FMT, offer another route for patients with recurrent C. diff.13PubMed. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives
Other infectious causes of colitis, such as Salmonella, Shigella, Campylobacter, and E. coli, are usually self-limiting and managed with fluids and supportive care. Antibiotics are reserved for severe cases, immunocompromised patients, or specific organisms like Shigella.
Ischemic Colitis
Ischemic colitis happens when blood flow to a segment of the colon drops suddenly, often at “watershed” areas where two arterial territories meet. It most commonly affects older adults with cardiovascular risk factors and typically presents as sudden abdominal cramping followed by bloody diarrhea. The majority of cases involve temporary, non-gangrenous ischemia that heals on its own with supportive care: IV fluids, bowel rest, and close monitoring.15PubMed Central. Management of ischemic colitis
Where things become dangerous is when the ischemia progresses to full-thickness bowel death, or gangrenous colitis. That scenario demands prompt surgical intervention, typically resection of the dead bowel segment.16PubMed Central. Surgical management and outcome in acute ischemic colitis The clinical challenge is recognizing which patients are headed toward gangrene before it is too late. Signs like peritonitis (a rigid, severely painful abdomen), metabolic acidosis, or persistent symptoms beyond a couple of days despite supportive care all raise the alarm. Immunosuppressive drugs have no role here, which is part of why distinguishing ischemic colitis from an IBD flare is so important.
Radiation Colitis
Patients who receive pelvic radiation therapy for cancers of the prostate, cervix, rectum, or bladder can develop radiation-induced damage to the colon or rectum. Acute radiation colitis during treatment usually resolves on its own. The more troublesome form is chronic radiation proctitis or colitis, which can develop months or even years after radiation ends, causing rectal bleeding, urgency, and diarrhea from abnormal blood vessels (telangiectasias) in the damaged tissue.
Argon plasma coagulation (APC), an endoscopic technique that uses a jet of ionized argon gas to cauterize bleeding vessels, is the most studied procedural treatment. In one study of 45 patients, APC successfully controlled bleeding in about 69% of cases, often requiring only one or two sessions.17PubMed Central. Efficacy and complications of argon plasma coagulation for hemorrhagic chronic radiation proctitis Patients with widespread telangiectasias or large ulcers were more likely to fail APC, sometimes requiring surgical diversion to control bleeding.17PubMed Central. Efficacy and complications of argon plasma coagulation for hemorrhagic chronic radiation proctitis In milder cases, APC can provide rapid and lasting symptom relief with relatively few complications.18PubMed Central. Argon Plasma Coagulation for the Treatment of Hemorrhagic Radiation Colitis Medical options like sucralfate enemas, hyperbaric oxygen therapy, and topical formalin are also used, though the evidence base for these is smaller.
Immune Checkpoint Inhibitor Colitis
Cancer immunotherapy drugs, particularly checkpoint inhibitors like ipilimumab and nivolumab, can provoke the immune system to attack the colon as a side effect. This type of colitis, often called immune-mediated diarrhea and colitis (IMDC), can be severe enough to require hospitalization and force patients off their cancer treatment. The first-line approach is high-dose corticosteroids, and many patients respond. For steroid-refractory cases, two biologic options have the most support: infliximab (which works faster) and vedolizumab (which is gut-selective).
A two-center observational study comparing the two found similar rates of clinical remission, around 88% to 89%. However, patients treated with vedolizumab had shorter steroid exposure, fewer hospitalizations, and shorter hospital stays than those given infliximab, though vedolizumab took a few days longer to kick in.19PubMed Central. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study The choice between them often comes down to how urgently symptoms need to be controlled, whether the patient is a candidate for restarting immunotherapy, and clinician experience.
When Surgery Becomes the Right Choice
Surgery is not a failure of medical therapy; for some patients it is the definitive treatment. In UC, about a quarter of patients eventually require removal of the colon.20PubMed Central. Ileal pouch surgery for ulcerative colitis The standard operation is a restorative proctocolectomy with ileal pouch-anal anastomosis, commonly called J-pouch surgery. The surgeon removes the entire colon and rectum, then fashions a reservoir from the end of the small intestine so the patient can still pass stool through the anus rather than needing a permanent ostomy bag.21PubMed Central. Technical aspects of ileoanal pouch surgery in patients with ulcerative colitis
The procedure is not without risks. A systematic review of outcomes found that short-term complications occurred in anywhere from 9% to 65% of patients, with infections and ileus (temporary bowel shutdown) being most common. Long-term, the most frequent issue is pouchitis, an inflammation of the newly created pouch, affecting roughly three in ten patients on average. Faecal incontinence and small bowel obstruction are other long-term concerns.22PubMed. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis Encouragingly, complication rates have been falling over time, and post-operative mortality sits around 1% across large studies. Surgery also eliminates the risk of colon cancer from UC, which is a significant motivator for patients with long-standing, poorly controlled disease.
Biosimilars and the Cost Question
One practical barrier to effective colitis treatment is cost. Biologic drugs can be extraordinarily expensive, and not all patients have access to them. Biosimilars, which are near-identical copies of original biologics with equivalent safety and efficacy, have begun to change that landscape. Multiple infliximab and adalimumab biosimilars are now available, and they are meaningfully cheaper than their reference products.23PubMed. Biobetters and biosimilars in inflammatory bowel disease For patients and health systems, this means broader access to the drugs that work best for moderate-to-severe disease. If your doctor switches you from a brand-name biologic to a biosimilar, the clinical evidence says you should expect the same results.
Cancer Surveillance for Long-Standing Colitis
People with long-standing inflammatory bowel disease affecting the colon carry an elevated risk of colorectal cancer. How aggressively you need to be surveilled depends on several factors: how much of the colon is involved, how well-controlled the inflammation has been, and whether you have coexisting conditions like primary sclerosing cholangitis. British Society of Gastroenterology guidelines recommend risk-stratified surveillance intervals. Patients with well-controlled, limited disease may need colonoscopy only every three years. Those with moderate ongoing inflammation, a history of dysplasia, or primary sclerosing cholangitis should be screened annually. And patients whose colons continue to show severe active inflammation despite optimized therapy should discuss colectomy with their team.24PubMed. British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease
When dysplasia (precancerous changes) is found, the approach depends on whether it is visible as a distinct lesion or scattered invisibly through the tissue. Visible lesions that can be completely removed endoscopically can be followed with more frequent surveillance. Invisible high-grade or multifocal dysplasia, on the other hand, is a strong indication for colectomy.25Gastroenterology. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review Keeping inflammation well-controlled is one of the most effective ways to reduce cancer risk, which is yet another reason to take maintenance therapy seriously even during symptom-free periods.
Age-Related Differences in Treatment
Treatment strategies shift at both ends of the age spectrum. Children and adolescents with IBD tend to receive immunomodulators and biologics earlier and more frequently than adults. A large Danish nationwide cohort study found that pediatric-onset UC patients were over twice as likely to receive immunomodulators compared with adult-onset patients, and about 27% more likely to receive biologics. At the other end, elderly-onset patients were far less likely to receive these steroid-sparing medications, even after two courses of systemic steroids.26PubMed Central. Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent – Results from a Danish nationwide cohort study, 2000-2018
The reluctance to escalate therapy in older adults comes partly from concerns about infection risk and frailty. High frailty in the Danish study was associated with lower use of biologics and immunomodulators. That caution is understandable, but it also means some older patients end up stuck on repeated steroid courses, which carry their own serious long-term risks: osteoporosis, diabetes, infections, and cataracts. A conversation about risk tolerance is worth having if you or an elderly family member is being managed with frequent steroids rather than a steroid-sparing alternative.
Curcumin and Other Complementary Add-Ons
Curcumin, the active compound in turmeric, is the most studied complementary therapy in UC. When added to standard mesalamine treatment, curcumin roughly doubled the rate of clinical remission compared with placebo in a meta-analysis of randomized controlled trials.27PubMed. Safety and efficacy of curcumin in the treatment of ulcerative colitis: An updated systematic review and meta-analysis of randomized controlled trials Endoscopic improvement also favored the curcumin group, and no serious side effects were reported.28PubMed Central. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials Those results are promising but come with caveats: the trials have been small, with high variability between studies, and the doses used (often 2 to 3 grams of curcumin daily) are far higher than what you would get from cooking with turmeric. Additionally, similar evidence does not yet exist for Crohn’s disease.
Mind-body interventions like psychotherapy, mindfulness-based stress reduction, yoga, and clinical hypnosis have emerging support as adjuncts to conventional treatment, particularly for managing the symptoms and quality-of-life burden of IBD. The brain-gut connection plays a bigger role in inflammatory bowel disease than was once appreciated, and these approaches can help reduce stress-related flare triggers and improve coping, even if they do not directly alter the underlying inflammation.29PubMed Central. Mind-Body Interventions for Pediatric Inflammatory Bowel Disease None of these should replace standard medical therapy, but for patients who feel that stress reliably worsens their symptoms, they are worth discussing with a care team.